Clinical TrialsSearch results
Number of results: 856
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Japanese Participants
- Inflammatory disease
- On Shintaro
- 2021-10-18
Completed
- A Phase 1, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy adult participants.
- Healthy adult participants
- Tanaka Tomoyuki
- 2022-08-31
Completed
- A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjects
- Prevention of COVID-19
- Inoguchi Akihiro
- 2021-03-10
Other
- A phase 2 neoadjuvant chemotherapy of Irinotecan (CPT-11) plus Nedaplatin (NDP) for stage 1b2 or 2 cervical cancer of the uterine cervix
- stage 1b2/2 cervical cancer
- Japanese Gynecologic Oncology Group
- 2006-12-21
Recruiting
- A phase 2 study of chemotherapy and durvalumab with TRT in patients with ED-SCLC
- extensive disease small cell lung cancer(ED-SCLC)
- Takayama Koichi
- 2021-02-24
Other
- A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Joseph Nacson
- 2023-02-12
Completed
- A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2021-10-29
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01